| Old Articles: <Older 44261-44270 Newer> |
|---|
 |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved.   |
The Motley Fool
September 22, 2010
Rich Smith |
Core Stock: Lockheed Martin 60 years, 1 trillion dollars. Can't go wrong. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
Baby Boomers Need This Investment As the first of the baby boomer generation begins to retire, individuals are going to be in for an unfortunate experience once they delve into their financial planning. |
The Motley Fool
September 22, 2010
Jeremy Myers |
Today's Buy Opportunity: Lumber Liquidators The Fool is going to buy this stock, and thinks you should, too. |
The Motley Fool
September 22, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Goldman drops U.S. Steel and Nucor to "neutral" and urges investors to roll their cash over into copper and Freeport McMoRan shares instead. |
The Motley Fool
September 22, 2010
Dan Caplinger |
Top Stocks for the Post-Recession Economy Recession's over. Here's where to put your money. |
The Motley Fool
September 22, 2010
Dan Caplinger |
When Sector ETFs Are a Bad Bet In many sectors, stock picking is essential. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Medicis Pharmaceutical Whiff on Revenues Next Quarter? Medicis Pharmaceutical's year-over-year revenue grew 23.2%, and its AR grew 40.5%. That's a yellow flag. |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
September 22, 2010
Dan Caplinger |
6 Stocks to Get Your Kids Through College The right investments make a huge difference. |
| <Older 44261-44270 Newer> Return to current articles. |
